Clinical TrialApr 21, 2026, 05:31 PM
BBOT Presents Positive Preclinical Data for BBO-10203 at AACR
AI Summary
BridgeBio Oncology Therapeutics (BBOT) presented new preclinical data for BBO-10203, a first-in-class covalent small molecule RAS:PI3K A breaker, at the AACR Annual Meeting 2026. The data showed BBO-10203 physically disrupts the interaction between RAS and PI3K A, leading to signaling inhibition and tumor regressions without observed hyperglycemia. The drug also demonstrated strong in vivo combination effects with HER2 inhibitors in HER2AMP models, and its mechanism is independent of RAS or PI3K A mutational status, potentially broadening its patient population. BBO-10203 is currently in a Phase 1 trial, with updated clinical data anticipated in the second half of 2026.
Key Highlights
- BBO-10203 disrupts RAS:PI3K A interaction without inhibiting PI3K A kinase activity.
- No hyperglycemia observed with BBO-10203 at 100 mg/kg QD.
- Induces tumor regressions at 30 mg/kg QD.
- Displays strong in vivo combination effects with HER2 inhibitors tucatinib or trastuzumab.
- Updated Phase 1 clinical data are expected in the second half of 2026.
Price Impact
More from BBOT